Ashfield, part of UDG Healthcare, has launched EmerGENE, a global end-to-end cell and gene therapy network approach designed to support small and midsize biotechs with the commercialization of their discoveries.   EmerGENE has been built by a multidisciplinary team that delivers expert-led guidance and services to biotechs throughout their entire clinical to commercial journey.   Combining experts from Ashfield Health, Ashfield Engage, and Ashfield Advisory, EmerGENE aims to unlock the potential...